The impact of baseline [−2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort
Active surveillance (AS) is one potential solution to avoiding the overtreatment of favorable prostate cancer. By handling the AS strategy more safely, tumor aggressiveness may be evaluated more accurately. The aim of the present study was to evaluate the predictive impact of baseline prostate-specific antigen (PSA) isoform [−2]proPSA (p2PSA)-related indices on the pathological reclassification at 1 year during an AS program.
Between 2002 and 2003, 134 males diagnosed with low-risk prostate cancer were registered in the Japanese multicenter study cohort as candidates for AS, and 118 (88 %) males actually proceeded to AS. Of the 118 patients, the 67 that underwent protocol biopsy at 1 year after beginning AS were enrolled in the present study. The predictive significance of various baseline clinicopathological features and p2PSA-related indices on pathological reclassification at 1 year after beginning AS were investigated.
The pathological reclassification rate was 37.3 %. According to the univariate analysis, prostate volume (p = 0.049), number of biopsy cores (p = 0.047), percentage of positive biopsy cores (p = 0.023), p2PSA to free PSA ratio (%p2PSA) (p = 0.003) and prostate health index (phi) (p = 0.010) at baseline were significantly different between the reclassification and non-reclassification groups. By multivariate logistic regression analysis, baseline %p2PSA (p = 0.008) and phi (p = 0.008) were the only independent predictive factors for pathological upgrade at 1 year after AS commencement.
Baseline %p2PSA and phi may predict the pathological reclassification at 1 year after starting AS, which could be due to the under detection of clinically significant prostate cancer at AS enrollment.
- Behbahani, TE, Ellinger, J, Caratozzolo, DG, Muller, SC (2012) Pathological outcomes of men eligible for active surveillance after undergoing radical prostatectomy: are results predictable?. Clin Genitourin Cancer 10: pp. 32-36 CrossRef
- Catalona, WJ, Partin, AW, Sanda, MG, Wei, JT, Klee, GG, Bangma, CH (2011) A multicenter study of [−2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185: pp. 1650-1655 CrossRef
- Guazzoni, G, Lazzeri, M, Nava, L, Lughezzani, G, Larcher, A, Scattoni, V (2012) Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 61: pp. 455-466 CrossRef
- Hugosson, J, Carlsson, S, Aus, G, Bergdahl, S, Khatami, A, Lodding, P (2010) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11: pp. 725-732 CrossRef
- Iremashvili, V, Pelaez, L, Manoharan, M, Jorda, M, Rosenberg, DL, Soloway, MS (2012) Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur Urol 62: pp. 462-468 CrossRef
- Ito, K, Miyakubo, M, Sekine, Y, Koike, H, Matsui, H, Shibata, Y (2012) Diagnostic significance of [−2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0–10.0 ng/ml range. World J Urol.
- Jansen, FH, Schaik, RH, Kurstjens, J, Horninger, W, Klocker, H, Bektic, J (2010) Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 57: pp. 921-927 CrossRef
- Mikolajczyk, SD, Marker, KM, Millar, LS, Kumar, A, Saedi, MS, Payne, JK (2001) A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61: pp. 6958-6963
- NCCN guidelines TM version 1.2013 prostate cancer, NCCN. org
- Peter, J, Unverzagt, C, Krogh, TN, Vorm, O, Hoesel, W (2001) Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 61: pp. 957-962
- Ross, AE, Loeb, S, Landis, P, Partin, AW, Epstein, JI, Kettermann, A (2010) Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 28: pp. 2810-2816 CrossRef
- Schroder, FH, Hugosson, J, Roobol, MJ, Tammela, TL, Ciatto, S, Nelen, V (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366: pp. 981-990 CrossRef
- Sugimoto, M, Shiraishi, T, Tsunemori, H, Demura, T, Saito, Y, Kamoto, T (2010) Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort. Jpn J Clin Oncol 40: pp. 973-979 CrossRef
- Tosoian, JJ, Loeb, S, Feng, Z, Isharwal, S, Landis, P, Elliot, DJ (2012) Association of [−2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 188: pp. 1131-1136 CrossRef
- The impact of baseline [−2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Journal of Cancer Research and Clinical Oncology
Volume 140, Issue 2 , pp 257-263
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Active surveillance
- Japanese cohort
- Low-risk prostate cancer
- Pathological reclassification
- Industry Sectors
- Author Affiliations
- 1. Department of Urology, Kagawa University Faculty of Medicine, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan
- 2. Department of Urology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan
- 3. Department of Pathologic Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan